跳转至内容
Merck
CN

SML1390

Sigma-Aldrich

Fexaramine

≥98% (HPLC)

别名:

3-[3-[(Cyclohexylcarbonyl)[[4′-(dimethylamino)[1,1′-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoic acid methyl ester

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C32H36N2O3
分子量:
496.64
MDL编号:
UNSPSC代码:
12352116
PubChem化学物质编号:
NACRES:
NA.77

质量水平

检测方案

≥98% (HPLC)

形式

powder

储存条件

desiccated

颜色

white to beige

溶解性

DMSO: 10 mg/mL, clear

储存温度

2-8°C

SMILES字符串

CN(C)C(C=C1)=CC=C1C2=CC=C(CN(C3=CC=CC(/C=C/C(OC)=O)=C3)C(C4CCCCC4)=O)C=C2

InChI

1S/C32H36N2O3/c1-33(2)29-19-17-27(18-20-29)26-15-12-25(13-16-26)23-34(32(36)28-9-5-4-6-10-28)30-11-7-8-24(22-30)14-21-31(35)37-3/h7-8,11-22,28H,4-6,9-10,23H2,1-3H3/b21-14+

InChI key

VLQTUNDJHLEFEQ-KGENOOAVSA-N

一般描述

Fexaramine belongs to the nuclear hormone receptor family.

应用

Fexaramine has been used to study its action on RANKL (receptor activator of nuclear factor-κB ligand)-induced osteoclastogenesis in mouse model.

生化/生理作用

Fexaramine is a potent and selective agonist of the bile acid sensor farnesoid X receptor (FXR) in the gut with an EC50 of 25 nM and no activity found for other nuclear receptors. Fexaramine induces enteric fibroblast growth factor 15 (FGF15), causing alterations in bile acid composition without activating FXR target genes in the liver. In mouse studies, fexaramine enhanced thermogenesis and browning of white adipose tissue while reducing diet-induced weight gain, body-wide inflammation and hepatic glucose production. Fexaramine also improved insulin responsiveness.
Fexaramine might regulate lipid and glucose metabolism and can serve as a therapeutic target in the treatment of fatty liver disease, type 2 diabetes and obesity. Fexaramine might mediate cholesterol homeostasis and promotes osteoblast differentiation and suppresses differentiation of osteoclast.

象形图

Exclamation mark

警示用语:

Warning

危险声明

预防措施声明

危险分类

Acute Tox. 4 Oral - Aquatic Chronic 4

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Farnesoid X receptor modulators (2011?2014): a patent review.
Sepe V, et al.
Expert Opinion on Therapeutic Patents, 25(8), 885-896 (2015)
Fexaramine Inhibits Receptor Activator of Nuclear Factor-?B Ligand-induced Osteoclast Formation via Nuclear Factor of Activated T Cells Signaling Pathways.
Zheng T, et al.
Journal of bone metabolism, 24(4), 207-215 (2017)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门